|Mr. John H. Johnson||Exec. Chairman||91.5k||N/A||1958|
|Mr. Richard S. Kollender CPA, M.B.A., CPA||Chief Operating Officer||70k||N/A||1969|
|Dr. Fredric Cohen||Chief Medical Officer||672.45k||N/A||1965|
|Dr. Per Marin M.D., Ph.D.||Founder and Sr. Clinical Advisor||N/A||N/A||N/A|
|Mr. Robert Matthew Lutz||Chief Financial Officer||N/A||N/A||1969|
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Strongbridge Biopharma plc’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 6; Compensation: 8.